Nimotuzumab for COVID-19: case series

Background: In COVID-19, EGFR production is upregulated in the alveolar epithelial cells. EGFR overexpression further activates STAT-3 and increases lung pathology. The EGFR pathway is also one of the major nodes in pulmonary fibrosis. Methods: Nimotuzumab, a humanized anti-EGFR antibody, was used t...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdo Cuza, Anselmo A, Ávila, Jonathan Pi, Martínez, Rafael Machado, González, José Jordán, Aspuro, Guillermo Pérez, Gutiérrez Martínez, Juan A, Suzarte, Mayra Ramos, Hernández, Danay Saavedra, Añé-Kouri, Ana L, Ramos, Tania Crombet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2021
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628863/
https://www.ncbi.nlm.nih.gov/pubmed/34806405
http://dx.doi.org/10.2217/imt-2021-0269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628863/
https://www.ncbi.nlm.nih.gov/pubmed/34806405
http://dx.doi.org/10.2217/imt-2021-0269

Ejemplares similares